Verici Dx plc (AIM:VRCI)

London flag London · Delayed Price · Currency is GBP · Price in GBX
3.375
0.00 (0.00%)
Feb 17, 2025, 8:00 AM GMT+1
-64.47%
Market Cap 7.58M
Revenue (ttm) 3.43M
Net Income (ttm) -3.81M
Shares Out 242.54M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 998
Average Volume 302,820
Open 3.288
Previous Close 3.375
Day's Range 3.288 - 3.375
52-Week Range 2.270 - 13.000
Beta 1.69
RSI 34.91
Earnings Date Apr 14, 2025

About Verici Dx

Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom. [Read more]

Industry Medical - Diagnostics & Research
Sector Healthcare
Founded 2020
Employees 14
Stock Exchange London Stock Exchange AIM
Ticker Symbol VRCI
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.